Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
Texture Features of Magnetic Resonance Images: an Early Marker of Post-stroke Cognitive Impairment.
Betrouni N, Yasmina M, Bombois S, Pétrault M, Dondaine T, Lachaud C, Laloux C, Mendyk AM, Henon H, Bordet R. Betrouni N, et al. Among authors: bombois s. Transl Stroke Res. 2020 Aug;11(4):643-652. doi: 10.1007/s12975-019-00746-3. Epub 2019 Nov 1. Transl Stroke Res. 2020. PMID: 31677092
Stroke is frequently associated with delayed, long-term cognitive impairment (CI) and dementia. Recent research has focused on identifying early predictive markers of CI occurrence. ...
Stroke is frequently associated with delayed, long-term cognitive impairment (CI) and dementia. Recent research has focused on identi …
Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke.
Zietemann V, Georgakis MK, Dondaine T, Müller C, Mendyk AM, Kopczak A, Hénon H, Bombois S, Wollenweber FA, Bordet R, Dichgans M. Zietemann V, et al. Among authors: bombois s. Neurology. 2018 Nov 13;91(20):e1838-e1850. doi: 10.1212/WNL.0000000000006506. Epub 2018 Oct 17. Neurology. 2018. PMID: 30333158
OBJECTIVE: To examine whether the Montreal Cognitive Assessment (MoCA) administered within 7 days after stroke predicts long-term cognitive impairment, functional impairment, and mortality. ...MoCA increased the area under the curve for predicting cognitive impairment (neu …
OBJECTIVE: To examine whether the Montreal Cognitive Assessment (MoCA) administered within 7 days after stroke predicts long-term cog …
Hippocampal Deformations and Entorhinal Cortex Atrophy as an Anatomical Signature of Long-Term Cognitive Impairment: from the MCAO Rat Model to the Stroke Patient.
Delattre C, Bournonville C, Auger F, Lopes R, Delmaire C, Henon H, Mendyk AM, Bombois S, Devedjian JC, Leys D, Cordonnier C, Bordet R, Bastide M. Delattre C, et al. Among authors: bombois s. Transl Stroke Res. 2018 Jun;9(3):294-305. doi: 10.1007/s12975-017-0576-9. Epub 2017 Oct 16. Transl Stroke Res. 2018. PMID: 29034421 Clinical Trial.
Stroke patients have an elevated risk of developing long-term cognitive disorders or dementia. The latter is often associated with atrophy of the medial temporal lobe. ...Hence, hippocampal deformations and entorhinal cortex atrophy were associated with long-term im …
Stroke patients have an elevated risk of developing long-term cognitive disorders or dementia. The latter is often associated with at …
Multiple Simultaneous Spontaneous Intracerebral Hemorrhages: A Rare Entity.
Chen Y, Hénon H, Bombois S, Pasquier F, Cordonnier C. Chen Y, et al. Among authors: bombois s. Cerebrovasc Dis. 2016;41(1-2):74-9. doi: 10.1159/000442475. Epub 2015 Dec 16. Cerebrovasc Dis. 2016. PMID: 26671248
BACKGROUND: In hospital databases, multiple simultaneous spontaneous intracerebral hemorrhages (ICH-m) account for 0.7-5.6% of all ICHs. Their long-term outcome has never been systematically and prospectively investigated. We aimed at identifying the long-term outco …
BACKGROUND: In hospital databases, multiple simultaneous spontaneous intracerebral hemorrhages (ICH-m) account for 0.7-5.6% of all ICHs. The …
A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. Lovestone S, et al. J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959. J Alzheimers Dis. 2015. PMID: 25537011 Clinical Trial.
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced n …
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, …